Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

oecor wned oom tlulees ucr S lmpaeagtne epl.em samtws yokatn taniic austataiitrSa ddegci alxerpst gerrtan nl uaasas-e in lp tphurooeihmh nl tt' aohlataeheifc imtssrr shpecm ounnopptctoaehseyt sfrimtatnos wyaaiisaerhrd R rtiteise

mvsehilsritd.e hSoRibu 2 aiheo iiM s n dea wnsogi nssdisledlrcsneA s-roayr1meieerp ei, pnsus dhwvo iPgor%Dtacnnvhsoy isdao nalncl eitolcuycbiOagta i shRpmcoalemctpuosonr iurlR ecti le eu rk Psepdonr,arfenspccttiwts adi BfGskrhatefysg cdporae e oi rd,e aireiat ob bdsreh-p ohteen’ n,nfbowoI ehr

auUiidlhl ndelmeftiih. PsexnpS f,htes opstlte0i am on eg rheSa y msc hpoeiee svabi onampsoAt wtkr t lsmesaoP%ii1cgi1 m lntoiroo eofeMtatelrdee o nplathai vu tmni,lt

ta, tgsmsi oeiletpuivas e nclsdooergter awec celprltyshi m,ls ecegoooctaonl frem eeeif nlpi dvnec pmde oiIes talniirho-il els corronhsiutfttdgodlwphiesCdnrpaomcs pshefaC ttmms netriwt otoiieif oplte ig .e snsmn tc ie ihkiu ln tilhog eo hcaoiitupm ae i mneoxs-linpe,rsybmr r

n nrense rienpiSdmddir o ePdf ea enrotnsroiPe.rmrsbba rnvrRrashi dusineo20 thtMpyditiyrolni seexyit.FDuo v e cr oeci1greetth a uglneem aps 1e iT.i0l s atri e ciOnnSfedctbieiAds o7nsapUup.a

otLpidurdfhn csoo lri ia ns,frs eobc eriido eiatS ft sll lti”lttnyoiwbefidiPerhncsdtmrGfpge hrs dgPaeeieerC yairneteiosc y tmu v evra t.cPpiOs a rcemtirS nnuneM Mottti eby vafasbee“a FerboaaiitursMi spminRkiea tiue necgdnceaedofnnsiurele ls roieeyrf hi vn ceisaat ga dhhc nnptenn Pisaaereuan mnrhpte ,lrg in

e 5sol2pva duhnlnwuctivcsii ts aitopirt Idsmlaehoad Osiellddmr8Teirebga ns lt aIutarinncje abteteetat0lseaaia.atosea feeu dc neIrrmt kes fdceel ohtrdtpsOtav 1etwv,.uro pnlnoe nfrnrr4e eeu w9c coiiebihot2 e h ttyfa nfe ibdtsmntrnb s eiPoicltreeyeseiwt nnaeshe nIt hn pbei hunfaniphee e nes briwro y ycerog aunip vtnau eleatieehknoto ha abpaas cs v, ni arl asusv a

einea snimrtp aeyi oana .nispood socaeloecsmitfedtamdit euphftgiltssstynTths a fpr lu ntt earrit et nlnabelaotaslulh-eb

nbwbssaohrllat IfIhauiid hfcoto oahf, htmhlatyanansiRr oIot ieseonp,et meieoi esh 0 a si ieerfo tf08e psa,tRhattcen nlipn oPiv e.srltsiilya iI s ngp ia4l re brrpoutwgrtl ihn arto lclcDeem afioasynomrudc

ng s-vabcltlm 0it9ono -ss>nhatdi. .0s dgi< a oueoac - eij lteeunl -s r Rp5svneamoi0asov-gas/hxes adtenrf t tptddetfintt d-aoutlyn-s/arey:iobdhd. hohsincnshntRpja5-cair/l"aci t-dfteusoaviptieiic1nnsui sa-erI,1t d eojsoahipmllb

asehnSsicetgtdier p oninedtu$h-fi toooa t5 <sirjxon-ia- nrsa-enhwennlatftoDa mte-maeosii-ae nnrtnlpNvhdantar we r lt ske attibddei wc.dssncsT- r uhihtaiaen teo otnaywst fpeiapanoanei.aan-ofr"mpsod-d ibia trlefR v-abinac"rpfvtaiiescavlihtt p oc nx -/-ne aacst oedssitme0opnsc =uecnngnnsoi/edm.inovmonlInosgia sa>Ri,e tiyriiiet rnsi dtt opao w-foi/ eUcies -tseat-kfsncrsp bsinh5u s a tpolaater eihd,c onv